Convergence Pharmaceuticals

Convergence Pharmaceuticals is focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The company was formed in 2010 as the first independent spin-out from GSK, has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels and other mechanisms. In 2015 it was acquired by Biogen Inc as a wholly owned subsidiary.